3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Small Cell Lung Carcinoma
9
Lung Neoplasms
4
Neoplasms
2
Desmoplastic Small Round Cell Tumor
2
Sarcoma, Ewing
1
Sarcoma
1
Platinum-Resistant Lung Small Cell Carcinoma
1
Neutropenia
1
Leiomyosarcoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
36
Bevacizumab
25
Cyclophosphamide
22
Blood Specimen Collection
18
Nivolumab
17
Carboplatin
15
Standard of Care
14
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
11
Fluorouracil
11
Doxorubicin
11
Cisplatin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Biopsy
8
130-nm albumin-bound paclitaxel
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
PM 01183
×
90 days
×
Clear all
NCT06088290
2026-05-15
SaLuDo
PharmaMar
Phase 3
Active not recruiting
455 enrolled
NCT05918640
2026-03-31
LiFFT
Children's Hospital of Philadelphia
Phase 1/2
Recruiting
63 enrolled